LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

2.22 -3.9

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.21

Max

2.31

Põhinäitajad
By Trading Economics
Sissetulek	14M -1M
Müük	16M 21M
Kasumimarginaal	-4.943
Töötajad	81
EBITDA	14M -996K

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+72.96% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	316M 1B
Eelmine avamishind	6.12
Eelmine sulgemishind	2.22

Uudiste sentiment

By Acuity

70%

30%

312 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. mai 2026, 22:47 UTC

Kuumad aktsiad

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. mai 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. mai 2026, 22:00 UTC

Suurimad hinnamuutused turgudel

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. mai 2026, 18:09 UTC

Suurimad hinnamuutused turgudel

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15. mai 2026, 16:02 UTC

Tulu

Suurimad hinnamuutused turgudel

Forward Industries Shares Fall on New Debt as Solana Value Drops

15. mai 2026, 14:55 UTC

Suurimad hinnamuutused turgudel

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15. mai 2026, 14:43 UTC

Suurimad hinnamuutused turgudel

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15. mai 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. mai 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. mai 2026, 20:19 UTC

Kuumad aktsiad

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. mai 2026, 19:41 UTC

Omandamised, ülevõtmised, äriostud

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. mai 2026, 18:35 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15. mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15. mai 2026, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15. mai 2026, 16:24 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15. mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15. mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15. mai 2026, 15:20 UTC

Tulu

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15. mai 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

72.96% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 72.96%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

312 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.